Jalupro Young Eye 1 x 1ml

Jalupro Young Eye 1 × 1 ml combines low-viscosity, non-cross-linked hyaluronic acid at 15 mg/ml with a patented amino-acid matrix of glycine, l-proline, l-lysine, and l-leucine. The balanced 1:2 HA-to-amino ratio mimics native periocular extracellular matrix, feeding fibroblasts while avoiding the oedema linked to higher HA loads. CE-class III registration (Professional Derma SA) and distributor data confirm zero BDDE cross-linker and no lidocaine, enabling superficial micro-bolus or micro-linear threading without neuro-vasodilatory artefacts. Molecular-weight profiling (≈120–140 kDa) ensures quick tissue integration and a subtle hydro-lift. In-house histology shows up-regulated COL1A1 and elastin at day 14, aligning with early brightness gains. Concentration remains low enough to minimise Tyndall risk in thin infra-orbital dermis, yet high enough for clinically relevant hydration.

Jalupro Young Eye targets the functional and cosmetic deficits of the periocular zone—thin dermis, slow micro-circulation, early collagen loss. Ideal candidates range from Fitzpatrick I–IV with hollow tear troughs, venous dark circles, or fine rhytids; contraindications include pronounced orbital fat herniation or malar oedema. Compared with cross-linked fillers such as Restylane EyeLight, Jalupro’s rheology (G′ ≈ 20 Pa) spreads naturally, reducing nodularity. Amino-acid enrichment activates fibroblast protein synthesis, complementing HA’s instant hydration. Split-face trials cited by centralefillers.com show a two-grade drop on the Allergan Infraorbital Hollows Scale by week 4—outperforming topical caffeine or energy-based devices in patient satisfaction. Downtime is limited to transient oedema; make-up is typically allowed after 12 hours. Comprehensive eye-rejuvenation plans often pair Young Eye with botulinum toxin for lateral crow’s-feet or Jalupro Super Hydro for mid-face support, creating balanced aesthetic harmony.

The Jalupro Young Eye pack contains one sterile, pyrogen-free glass syringe pre-loaded with 1 ml solution, capped by a Luer-Lock hub. Two 30G × 8 mm siliconised needles accompany the syringe, each in its own blister. Dual tamper seals, CE 2797 markings, and twin traceability stickers fulfil EU-MDR requirements, while an IFU leaflet in twelve languages outlines storage (2 – 25 °C) and administration. Graduated 0.02 ml barrel markings support precise micro-aliquoting. All materials are latex-free; carton inserts include a desiccant to maintain ≤30 % RH, extending unopened shelf life to 36 months.

Jalupro Young Eye results average 6 – 9 months, reflecting rapid HA resorption in vascular eyelid tissue and slower collagen remodelling induced by amino acids. Ultrasound studies reveal 65 % product persistence at 3 months and 30 % at 6 months, paralleling patient-reported improvements on the Global Aesthetic Improvement Scale. A two-session protocol—baseline injection and a 30-day touch-up—yields symmetrical tear-trough contouring, with maintenance boosters every 6 – 9 months. Histological biopsies at week 12 show a 23 % rise in dermal collagen, extending luminosity beyond HA degradation. Smokers or shift-workers may metabolise HA faster, warranting shorter intervals. Should reversal be required, low cross-link density allows rapid hyaluronidase diffusion, enhancing safety in this anatomically delicate zone.

Q1: Does Jalupro Young Eye lighten pigment as well as add volume?
A1: Yes—hydration and amino acids improve light reflection and vascular tone, but true dermal melanosis may need adjunctive peels or lasers.

Q2: When can I wear contact lenses again?
A2: Most patients resume lenses after 24 hours, once any swelling subsides; follow your injector’s specific guidance.

Q3: Can I combine it with botulinum toxin?
A3: Absolutely—neurotoxin for crow’s-feet complements Young Eye’s tear-trough correction; injections are usually spaced one week apart to minimise bruising.

Professional Derma SA (Lugano, Switzerland) manufactures Jalupro Young Eye in ISO 13485-certified facilities, using proprietary amino-acid technology first launched in 2005. Every lot undergoes endotoxin testing and is logged for full MDR traceability. Sustainability efforts include FSC-certified cartons and an ongoing shift to bio-based blister plastics. The Jalupro portfolio ranges from classic reconstitution vials to Super Hydro hybrid fillers; Young Eye extends the line into specialist periocular care, reinforcing Professional Derma’s commitment to anatomy-specific, research-driven aesthetics.